PharmaResources (Shanghai) Co., Ltd Class A

PharmaResources (Shanghai) Co., Ltd Class A

SSZSE:301230
28.40
CNY
-1.48
(-4.95%)
0.16EPS
241.66P/E
6.98BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
1.56
0.62
0.9
1.06
0.98
1.86
2.11
3.3
3.33
2.7
2.94
3.86
4.04
Basic EPS, GAAP
0.02
0.28
0.05
0.11
0.16
0.07
0.36
0.36
0.54
0.47
0.21
0.09
0.19
0.16
Free Cash Flow per Basic Share
0.05
0.29
-0.11
0.12
0.05
0.04
0.05
0.16
0.1
-0.17
-1.26
-0.15
0.52
- -
Dividend per Share
- -
0.05
0.02
0.02
0.01
0.09
0.01
0.44
0.01
0.01
0.21
0.27
0.3
0.28
Book Value per Share
0.46
0.56
0.61
0.71
1.24
1.16
1.52
1.93
2.56
6.12
6.14
5.69
5.53
5.59
Tangible Book Value per Share
0.38
0.5
0.54
0.65
1.18
1.1
1.46
1.87
2.5
6.07
6.1
5.64
5.49
5.54
Basic Weighted Avg Shares
131
50
122
118
127
128
132
134
136
144
181
185
178
180
Sales/Revenue/Turnover
33
78
76
107
135
126
245
283
448
479
490
544
688
725
Operating Margin (%)
3.51
19.72
10.29
13.58
18.87
9.9
21.5
23.13
20.87
13.96
8.78
-0.58
6.34
5.96
Depreciation Expense
1
5
5
6
6
8
9
12
24
28
36
49
51
- -
Net Income, GAAP
2
14
6
14
20
9
47
49
74
67
38
17
34
29
Effective Tax Rate (%)
13.62
12.64
26.14
12.97
10.2
19.55
9.17
11.82
14.68
7.88
- -
- -
- -
- -
Profit Margin (%)
7.5
17.91
8.16
12.62
14.79
7.3
19.27
17.21
16.42
14.03
7.68
3.14
4.98
3.95
Working Capital
-1
11
11
24
78
70
102
142
149
836
540
429
410
388
LT Debt
- -
- -
- -
- -
- -
- -
- -
18
77
80
172
151
129
111
Total Equity
60
74
80
94
163
152
200
263
348
1,113
1,118
1,033
1,004
1,014
Return on Invested Capital (%)
- -
9.82
4.59
8.42
13.07
5.99
25.09
19.29
19.83
8.09
- -
- -
- -
- -
Return on Capital (%)
- -
16.65
7.33
13.06
14.57
6.93
27.82
20.59
21.45
8.57
- -
- -
- -
- -
Return on Common Equity (%)
- -
20.75
8.02
15.52
15.51
5.82
26.81
21.02
24.06
9.19
3.37
1.59
3.37
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
34
29
34
LT Borrowings
- -
- -
- -
LT Finance Leases
126
115
111
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
181
181
181
Market Capitalization
5,669
5,142
6,983

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
578
565
543
Cash, Cash Equivalents & STI
288
282
269
Accounts Receivable, Net
134
152
144
Inventories
91
73
67
Total Current Liabilities
154
168
155
Payables & Accruals
- -
- -
- -
ST Debt
34
29
34
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.89%
48.37%
-2.76%
Free Cash Flow
-5.55%
-3.26%
-423.04%
Net Income, GAAP
57.41%
8.91%
100.75%
Sales/Revenue/Turnover
27.58%
21.02%
26.43%
Total Cash Common Dividend
1,010.69%
958.28%
9.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
131
135
126
153
544
2025
169
183
- -
174
688
2026
172
192
186
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.07
- -
0.01
0.09
2025
0.07
0.07
- -
- -
0.19
2026
0.13
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.19
0.01
0.08
0.27
2025
- -
- -
- -
0.05
0.3
2026
0.07
0.02
0.15
- -
- -

Company Description

CEO
Ping Chen
Full Time Employees
1,155
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Shanghai China
IPO Date
Nov 1, 2022
Business
PharmaResources (Shanghai) Co., Ltd. is a China-based contract research, development, and manufacturing organization (CRO/CDMO) that provides integrated, end-to-end drug discovery, chemical process development, and commercial manufacturing services to the global pharmaceutical and biotechnology industries. Founded in 2007 and headquartered in Shanghai, China, the company operates primarily through three core business segments: Drug Discovery (CRO), Process Research and Development (CRO/CDMO), and Commercial Manufacturing (CDMO/CMO). The company offers a comprehensive portfolio of products and technical services across the small molecule drug development lifecycle, including: drug discovery services comprising target validation, hit-to-lead identification, lead optimization, custom organic synthesis, medicinal chemistry, structure-based and ligand-based drug design, in vitro and in vivo drug metabolism and pharmacokinetics (DMPK) evaluations, and preliminary safety profiling; artificial intelligence-driven drug discovery (AIDD) and computer-aided drug design (CADD) through its proprietary DiOrion platform, featuring modules such as DiOrion-PepGen for cyclic peptide engineering and the DiOrion-GPT biomedical language model for target identification and molecular optimization across complex modalities including antibody-drug conjugates (ADCs) and proteolysis targeting chimeras (PROTACs); process chemistry and development services encompassing synthetic route scouting, reaction engineering, process safety assessment, polymorphic form screening, crystallization process development, analytical method development and validation, and flow chemistry technology application for hazardous or complex reaction conditions; and cGMP-compliant commercial production of registered starting materials (RSMs), advanced regulatory intermediates, and active pharmaceutical ingredients (APIs) ranging from kilogram to multi-ton scales, supporting commercial products and development-stage compounds such as ticagrelor, oxiracetam, L-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2. PharmaResources serves innovative biopharmaceutical companies, multinational pharmaceutical corporations, and research institutions across North America, Europe, and the Asia-Pacific region. The company conducts its research, development, and administrative activities across multiple sites in Shanghai and Chengdu, while operating large-scale cGMP manufacturing facilities through its primary production subsidiary, PharmaResources (Kaiyuan) Pharmaceutical Co., Ltd. in Liaoning Province, equipped with more than 120 reaction vessels ranging in capacity from 200 liters to 10,000 liters. The company also maintains international customer service, business development, and project management operations via its overseas subsidiary, PharmaResources, LLC, located in the United States. In recent developments, PharmaResources has completed the construction and operational transition of its Phase II and Phase III preclinical new drug research and development base expansion projects, substantially increasing laboratory capacity by adding specialized CDMO facilities in Shanghai and expanded medicinal chemistry and DMPK research space in Chengdu. The company is actively executing a commercial manufacturing capacity ramp-up at its Kaiyuan production facility, deploying modular continuous flow microchannel reaction platforms to enhance throughput, safety, and cost efficiency for energetic and complex chemistries. Furthermore, PharmaResources has expanded the deployment of its proprietary DiOrion AI platform, integrating multi-modal AI models directly with internal wet-lab synthesis and biological testing workflows to support more than one hundred external collaborative drug discovery programs. The company has also completed corporate governance adjustments and capital restructuring initiatives, including equity distribution and capital reserve transfers, to support ongoing operational scaling and expanded international service engagements.